Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001373604-25-000024
Filing Date
2025-02-13
Accepted
2025-02-13 17:02:36
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4824
  Complete submission text file 0001373604-25-000024.txt   6599
Mailing Address 156 S. FIRST STREET ZIONSVILLE IN 46077
Business Address 156 S. FIRST STREET ZIONSVILLE IN 46077 317-344-6689
BML Investment Partners, L.P. (Filed by) CIK: 0001373604 (see all company filings)

EIN.: 383708345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 245 HAMMERSMITH ROAD LONDON X0 W6 8PW
Business Address 245 HAMMERSMITH ROAD LONDON X0 W6 8PW 44 (0)20 8154 4600
Achilles Therapeutics plc (Subject) CIK: 0001830749 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92487 | Film No.: 25621404
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)